Do chemicals make you fat?

The EU research project EDCMET is investigating the effect of endocrine disruptors on metabolism

28-Jan-2019 - January 2019 saw the launch of the EU research project EDCMET, in which scientists from the German Federal Institute for Risk Assessment (BfR) are also involved. EDCMET stands for "Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome path-ways" and is ...

DSM invests EUR 2 million in Finnish genetic discovery company

07-Sep-2007 - DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has made an equity investment of EUR 2 million in Jurilab Oy, a Finnish company specialized in the discovery of gene-disease associations and their application to healthcare. Following investments in Sciona and ...

Frost: Strategic Analysis of the Opportunities for the Pharmaceutical and Biotechnology Industry in the 'New' EU Countries

Pharmaceutical and Biotechnology Industry in the 'New' EU Countries Presents Considerable Potential, Parallel Imports Remain a Challenge

25-Feb-2005 - In contrast to subdued growth in the pharmaceutical markets of the former 15-state European Union (EU), pharmaceutical markets in the 'new' EU accession markets are expanding vibrantly. While the former has been increasing at eight per cent annually, the latter has been growing at the rate of ...

Takeda to Acquire Syrrx

09-Feb-2005 - Takeda Pharmaceutical Company Limited announced that Takeda and Syrrx Inc. agreed on February 5, 2005 (PST) to merge Syrrx, Inc. into the Takeda Group. The merger is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is subject to the satisfaction of other customary ...

CareX and Chemical Diversity Labs announce research agreement

23-Oct-2002 - French biopharmaceutical company CareX S.A. and San Diego based Chemical Diversity Labs, Inc. announced that they have formed a research collaboration that applies methods of rational drug design to Focused Library Screening of bio-active substances. Under the terms of the agreement, Chemical ...

Millennium and COR Therapeutics agree to merge

07-Dec-2001 - Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. have signed a definitive agreement for Millennium to acquire COR in a stock- for-stock exchange valued at $2.0 billion. The combined company will be named Millennium Pharmaceuticals, Inc., with worldwide headquarters in Cambridge, ...

Novartis granted exclusive rights for development and commercialization of a novel insulin sensitizer from Dr. Reddy's

30-May-2001 - Novartis Pharma AG and Dr. Reddy's Laboratories Ltd announced today that they have entered a licensing agreement for a novel anti-diabetes agent. Under terms of the agreement Dr. Reddy's will grant Novartis worldwide exclusive rights to development and commercialization of their insulin ...

Knoll AG: Pharma business sold for $6.9 billion:

18-Dec-2000 - BASF (NYSE: BF) is focusing on the strengths of its portfolio in order to broaden its base for further profitable growth. That is why the world's biggest chemical company is selling its pharmaceuticals operations for $6.9 billion ...

Inauguration of new Roche Pharma Research building in Basel

06-Dec-2000 - On 5 December, after a construction phase lasting two years, Roche has inaugurated the new Pharma Research Building designed by the Basel architects Herzog & de Meuron. Planning and construction of the new Research Building cost a total of 150 million Swiss francs. This major investment ...

Abgenix And Curagen To Develop Up To 250 Antibody Therapeutic Candidates

30-Nov-2000 - Abgenix, Inc. (Nasdaq: ABGX), an antibody-based biopharmaceutical company and CuraGen Corporation (Nasdaq: CRGN), an integrated genomics-based drug discovery and development company, announced today the expansion of their strategic alliance to develop and commercialize genomics-based antibody ...